Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction

References

• Aso, N., Tamura, A., and Nasu, M., 2004. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. The American journal of cardiology, 94 (11), 1468–1470.
   PubMed Web of Science ®Google Scholar
• Cheng, J.M., et al., 2013. Biomarkers of heart failure with normal ejection fraction: a systematic review. European journal of heart failure, 15 (12), 1350–1362.
   PubMed Web of Science ®Google Scholar
• Duca, F., et al., 2016. Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study. Circulation: cardiovascular imaging, 9 (12), e005277.
   PubMed Web of Science ®Google Scholar
• Edwards, N.C., et al., 2015. Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease. The American journal of cardiology, 115 (9), 1311–1317.
   PubMed Web of Science ®Google Scholar
• Fujimoto, N., et al., 2009. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. Journal of cardiac failure, 15 (10), 898–905.
   PubMedGoogle Scholar
• Hessel, M.H., et al., 2007. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. European journal of heart failure, 9 (10), 1058–1063.
   PubMed Web of Science ®Google Scholar
• Kanagala, P., et al., 2019. Relationship between focal and diffuse fibrosis assessed by cmr and clinical outcomes in heart failure with preserved ejection fraction. JACC cardiovascular imaging, 12(11 Pt 2):2291–2301.
   PubMed Web of Science ®Google Scholar
• Kanagala, P., et al., 2018. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction - implications for clinical trials. Journal of cardiovascular magnetic resonance: official journal of the society for cardiovascular magnetic resonance, 20 (1), 4.
   PubMedGoogle Scholar
• Karamitsos, T.D., et al., 2009. The role of cardiovascular magnetic resonance imaging in heart failure. Journal of American College of cardiology, 54 (15), 1407–1424.
   PubMed Web of Science ®Google Scholar
• Kato, S., et al., 2015. Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. International journal of cardiology, 191, 314–319.
   PubMed Web of Science ®Google Scholar
• Kitaoka, H., et al., 2012. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. Journal of cardiology, 59 (2), 209–214.
   PubMed Web of Science ®Google Scholar
• Komajda, M., and Lam, C.S., 2014. Heart failure with preserved ejection fraction: a clinical dilemma. European heart journal, 35 (16), 1022–1032.
   PubMed Web of Science ®Google Scholar
• Lam, C.S., et al., 2011. Epidemiology and clinical course of heart failure with preserved ejection fraction. European journal of heart failure, 13 (1), 18–28.
   PubMed Web of Science ®Google Scholar
• Liabeuf, S., et al., 2011. High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis, 215 (1), 116–124.
   PubMed Web of Science ®Google Scholar
• Mascherbauer, J., et al., 2013. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circulation: cardiovascular imaging, 6 (6), 1056–1065.
   PubMed Web of Science ®Google Scholar
• Nishioka, T., et al., 2010. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. American journal of physiology. Heart and circulatory physiology, 298 (3), H1072–8.
   PubMed Web of Science ®Google Scholar
• Okamoto, H., and Imanaka-Yoshida, K., 2012. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovascular therapeutics, 30 (4), e198-209–e209.
   PubMed Web of Science ®Google Scholar
• Owan, T.E., et al., 2006. Trends in prevalence and outcome of heart failure with preserved ejection fraction. The new England journal of medicine, 355 (3), 251–259.
   PubMed Web of Science ®Google Scholar
• Palau, P., et al., 2016. Six-minute walk test in moderate to severe heart failure with preserved ejection fraction: Useful for functional capacity assessment? International journal of cardiology, 203, 800–802.
   PubMed Web of Science ®Google Scholar
• Paulus, W.J., and Tschope, C., 2013. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American college of cardiology, 62 (4), 263–271.
   PubMed Web of Science ®Google Scholar
• Pencina, M.J., D'Agostino, R.B., and Steyerberg, E.W., 2011. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statistics in medicine, 30 (1), 11–21.
   PubMed Web of Science ®Google Scholar
• Phan, T.T., et al., 2012. The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics. International journal of cardiology, 158 (3), 337–343.
   PubMed Web of Science ®Google Scholar
• Pitt, B., et al.,; TOPCAT Investigators. 2014. Spironolactone for heart failure with preserved ejection fraction. The new England journal of medicine, 370 (15), 1383–1392.
   PubMed Web of Science ®Google Scholar
• Ponikowski, P., et al.,; AUTHORS/TASK FORCE. 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 37, 2129–2200.
   PubMed Web of Science ®Google Scholar
• Rector, T.S., Kubo, S.H., and Cohn, J.N., 1993. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. The American journal of cardiology, 71 (12), 1106–1107.
   PubMed Web of Science ®Google Scholar
• Roy, C., et al., 2018. Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction. Journal of cardiovascular magnetic resonance, 20 (1), 55.
   PubMedGoogle Scholar
• Sato, A., et al., 2012. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. Journal of cardiac failure, 18 (6), 480–486.
   PubMed Web of Science ®Google Scholar
• Schelbert, E.B., et al., 2017. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome. JAMA cardiology, 2 (9), 995–1006.
   PubMed Web of Science ®Google Scholar
• Shimojo, N., et al., 2015. Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin αVβ3/nuclear factor-κB/interleukin-6 axis. Hypertension (Dallas, Tex: 1979), 66 (4), 757–766.
   PubMed Web of Science ®Google Scholar
• Singh, A., et al., 2017. Symptom onset in aortic stenosis: relation to sex differences in left ventricular remodeling. JACC cardiovascular imaging. 12(1):96–105.
   PubMed Web of Science ®Google Scholar
• Tang, H., et al., 2016. 384-Well multiplexed luminex cytokine assays for lead optimization. Journal of biomolecular screening, 21 (6), 548–555.
   PubMedGoogle Scholar
• Terasaki, F., et al.,; Study Group for Intractable Diseases by a Grant from The Ministry of Health, Labor and Welfare of Japan. 2007. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circulation journal, 71, 327–330.
   PubMed Web of Science ®Google Scholar
• Vassiliou, V.S., et al., 2016. Left atrial dilation in patients with heart failure and preserved ejection fraction: Insights from cardiovascular magnetic resonance. International journal of cardiology, 210, 158–160.
   PubMed Web of Science ®Google Scholar
• Yao, H.C., et al., 2013. Prognostic values of serum tenascin-C in patients with ischaemic heart disease and heart failure. Heart lung and circulation, 22 (3), 184–187.
   PubMed Web of Science ®Google Scholar